Navigation Links
Cardium Announces New Excellagen FDA 510(k) Submission Based On Expanded Structural And Functional Properties
Date:8/5/2013

SAN DIEGO, Aug. 5, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced that it has filed a new 510(k) submission for its current FDA-cleared Excellagen® advanced wound care product to reflect additional and specific structural and functional properties of Excellagen based on the Company's supplemental research and development activities.    

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

The new 510(k) submission further characterizes Excellagen as a dermal wound matrix with structural and functional properties that play essential roles in wound healing.  Excellagen is a physiologically formulated homogenate of bovine dermal Type I collagen in its native, 3-dimensional fibrillar structural configuration that provides a scaffold for cellular infiltration and wound granulation, and which activates blood platelets that can trigger the release of essential growth factors.  The submission is supported by in vitro research findings including electron microscopy data that should allow for more specific labeling to include the unique structural and biological properties of Excellagen and its utilization to potentially enhance platelet activation when used in concert with Platelet Rich Plasma (PRP) therapy.  In addition, the Company plans to modify Excellagen's packaging to include individually pouched applicator syringes and a large volume syringe applicator to allow for easier use in larger-sized wounds such as those found in limb salvage, orthopedic surgery and other surgical applications.

"We believe the research data provided to the FDA in our recent 510(k) submission provide further insight into the significantly accelerated and activated healing response seen with our Excellagen advanced wound care product," stated Christopher J. Reinhard<
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cardium Reports On New Excellagen Distribution Agreement With AvKARE For Veterans Hospitals And Other Governmental Medical Facilities
2. Cardium Completes Preferred Stock Financing
3. Cardium Announces Reverse Stock Split
4. Cardium Announces Initial Voting Results And Temporary Adjournment of Annual Meeting To Be Reconvened On June 21, 2013
5. Cardium Presents First Quarter 2013 Financial Results And Reports On Recent Developments
6. Cardium Announces Generx Publication In Molecular Therapy
7. Cardium Announces Excellagen Presentation at the Symposium on Advanced Wound Care Spring 2013 Meeting
8. Cardium Presents Year-End 2012 Financial Results And Recent Developments
9. Cardium Announces $4.0 Million Preferred Stock Financing And Reports On Exchange Listing Compliance
10. Cardium Receives ISO Certification for Excellagen
11. Cardium Announces Presentaton at The 2013 Cell & Gene Therapy Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015  AccuTec Blades, Inc. today ... Industrial Blades division.  EPC announced in May 2015 its ... Verona, Virginia and Obregon, ... the sale process. Rick Gagliano ... AccuTec Blades said, "Our new name, AccuTec Blades, reflects ...
(Date:9/1/2015)... , Sept. 1, 2015 Nevro Corp. ... that is providing innovative evidence-based solutions for the treatment ... submitted its preliminary response to the Patent Trial and ... inter partes review (IPR), filed by a unit ... claims in U.S. Patent No. 8,359,102 (the ,102 patent). The ...
(Date:9/1/2015)... YEHUDA, Israel , Sept. 1, 2015 ... ), a leading innovator of less invasive, miniaturized circulatory ... heart failure, announced today that it has entered into ... . ("Valtech").  Valtech is a privately held company that ... valve repair and replacement devices for the treatment of ...
Breaking Medicine Technology:AccuTec Blades, Inc. Announces Acquisition of Industrial Blades Division from Edgewell Personal Care Company 2Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 3HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 4HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 5HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 6HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 7HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 8HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 9HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 10
... March 30, 2011 Regado Biosciences, a privately held ... control agents, announced that David J. Mazzo, PhD, President ... Company,s 10th Annual Healthcare Conference at the New York ... 6, 2011 at 11:20 a.m. EDT.  The presentation will ...
... Inc. (Nasdaq: ABAX ), a medical products company ... chairman and chief executive officer,  will present at the 10th ... 8:40 a.m. ET. The conference will be held at the ... About Abaxis Abaxis develops, manufactures and markets portable blood ...
Cached Medicine Technology:Regado Biosciences to Present at the Needham & Company's 10th Annual Healthcare Conference in New York City 2Regado Biosciences to Present at the Needham & Company's 10th Annual Healthcare Conference in New York City 3
(Date:9/1/2015)... ... ... From Aug. 17-21, Calvary Hospital hosted the 18th consecutive session of its bereavement ... place at Kingsborough Community College in Brooklyn in each of the past three years. ... two junior counselors who were campers themselves just a few years ago. , The ...
(Date:9/1/2015)... ... September 01, 2015 , ... Horizon Blue Cross Blue Shield of New Jersey ... in the LATINA Style 50 Report that recognizes companies that provide the best career ... Horizon BCBSNJ climbs from number 24 to 21 of the 50 Best Companies for ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... prevent different malignancies. Some options for cancer treatment are available belonging to ... distinctive approach is necessary for effective treatment. Several molecules have been discovered ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... delivery options, Blue Cross and Blue Shield of Minnesota (Blue Cross) has announced ... , Based in San Francisco, Doctor On Demand provides immediate access to ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... creates negative pressure inside a wound to remove exudates, fluid, and infectious materials ... (comprising portable devices, stand-alone devices, disposable devices, and canisters, etc.) is projected to ...
Breaking Medicine News(10 mins):Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3
... new study it was found that researchers at the UC ... amino acids // . The speciality of this discovery is ... and specificity towards leukemic and lymphoma cells. Hence researchers say ... deliver anti-cancer drugs. ,The study results were published ...
... nonepileptic seizures, or psychogenic seizures are often misdiagnosed as ... //whereas epilepsy is caused by the abnormal electrical activity ... seizures are similar to epileptic seizures, they can be ... June 13, 2006, issue of Neurology, the scientific journal ...
... that a short course of a drug could relieve severe ... million youngsters in mainly poor countries each year. ... Romark Laboratories under the brand name Alinia, had been found ... in young children with a severe form of the illness. ...
... to completely avoid consuming Vitamin E supplements, as this is ... ,A leading obstetrician, Prof Stuart Campbell, has appealed to ... following clinical trials that have revealed that this vitamin can ... known to increase the rates of still births and cause ...
... news agency reports, northern Ukraine faces the initial attack of ... destroy domestic poultry //. ,In southern Ukraine, ... peninsula, firstly diagnosed a case of avian flu in last ... to villagers and done so by the Ukraine's Emergencies Ministry, ...
... scientists have claimed that they have identified three new cataract-causing ... in families in India. ,Scientists from the Center ... with researchers from the National Institute of Health, USA and ... 30 years of research in the field of ophthalmology, to ...
Cached Medicine News:Health News:New Molecular Treatment Identified To Treat Blood Cell Cancers 2Health News:Clues To Identify Psychological Seizures 2Health News:Clues To Identify Psychological Seizures 3Health News:Indian Scientists Identify Cataract Causing Genes 2
The NexGen CR femoral component is intended for patients who, in the physician's judgement, have good bone stock and whose ligaments provide adequate mediolateral, anteroposterior, and varus/valgus s...
Cruciate retaining, posterior stabilized and constrained components....
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
...
Medicine Products: